Literature DB >> 18499743

N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I.

Kevin S Thorneloe1, Anthony C Sulpizio, Zuojun Lin, David J Figueroa, Angela K Clouse, Gerald P McCafferty, Tim P Chendrimada, Erin S R Lashinger, Earl Gordon, Louise Evans, Blake A Misajet, Douglas J Demarini, Josephine H Nation, Linda N Casillas, Robert W Marquis, Bartholomew J Votta, Steven A Sheardown, Xiaoping Xu, David P Brooks, Nicholas J Laping, Timothy D Westfall.   

Abstract

The transient receptor potential (TRP) vanilloid 4 (TRPV4) member of the TRP superfamily has recently been implicated in numerous physiological processes. In this study, we describe a small molecule TRPV4 channel activator, (N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), which we have used as a valuable tool in investigating the role of TRPV4 in the urinary bladder. GSK1016790A elicited Ca2+ influx in mouse and human TRPV4-expressing human embryonic kidney (HEK) cells (EC50 values of 18 and 2.1 nM, respectively), and it evoked a dose-dependent activation of TRPV4 whole-cell currents at concentrations above 1 nM. In contrast, the TRPV4 activator 4alpha-phorbol 12,13-didecanoate (4alpha-PDD) was 300-fold less potent than GSK1016790A in activating TRPV4 currents. TRPV4 mRNA was detected in urinary bladder smooth muscle (UBSM) and urothelium of TRPV4+/+ mouse bladders. Western blotting and immunohistochemistry demonstrated protein expression in both the UBSM and urothelium that was absent in TRPV4-/- bladders. TRPV4 activation with GSK1016790A contracted TRPV4+/+ mouse bladders in vitro, both in the presence and absence of the urothelium, an effect that was undetected in TRPV4-/- bladders. Consistent with the effects on TRPV4 HEK whole-cell currents, 4alpha-PDD demonstrated a weak ability to contract bladder strips compared with GSK1016790A. In vivo, urodynamics in TRPV4+/+ and TRPV4-/- mice revealed an enhanced bladder capacity in the TRPV4-/- mice. Infusion of GSK1016790A into the bladders of TRPV4+/+ mice induced bladder overactivity with no effect in TRPV4-/- mice. Overall TRPV4 plays an important role in urinary bladder function that includes an ability to contract the bladder as a result of the expression of TRPV4 in the UBSM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499743     DOI: 10.1124/jpet.108.139295

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  167 in total

1.  TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice.

Authors:  Shaik O Rahaman; Lisa M Grove; Sailaja Paruchuri; Brian D Southern; Susamma Abraham; Kathryn A Niese; Rachel G Scheraga; Sudakshina Ghosh; Charles K Thodeti; David X Zhang; Magdalene M Moran; William P Schilling; Daniel J Tschumperlin; Mitchell A Olman
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 2.  Vanilloid and melastatin transient receptor potential channels in vascular smooth muscle.

Authors:  Scott Earley
Journal:  Microcirculation       Date:  2010-05       Impact factor: 2.628

Review 3.  From urgency to frequency: facts and controversies of TRPs in the lower urinary tract.

Authors:  Roman Skryma; Natalia Prevarskaya; Dimitra Gkika; Yaroslav Shuba
Journal:  Nat Rev Urol       Date:  2011-10-04       Impact factor: 14.432

4.  Optical recording reveals novel properties of GSK1016790A-induced vanilloid transient receptor potential channel TRPV4 activity in primary human endothelial cells.

Authors:  Michelle N Sullivan; Michael Francis; Natalie L Pitts; Mark S Taylor; Scott Earley
Journal:  Mol Pharmacol       Date:  2012-06-11       Impact factor: 4.436

Review 5.  International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family.

Authors:  Long-Jun Wu; Tara-Beth Sweet; David E Clapham
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

6.  Forward genetic analysis reveals multiple gating mechanisms of TRPV4.

Authors:  Stephen Loukin; Zhenwei Su; Xinliang Zhou; Ching Kung
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

7.  Membrane potential governs calcium influx into microvascular endothelium: integral role for muscarinic receptor activation.

Authors:  Erik J Behringer; Steven S Segal
Journal:  J Physiol       Date:  2015-09-13       Impact factor: 5.182

8.  New life in overactive bladder. Focus on "Novel regulatory mechanism in human urinary bladder: central role of transient receptor potential melastatin 4 channels in detrusor smooth muscle function".

Authors:  Kirk L Hamilton
Journal:  Am J Physiol Cell Physiol       Date:  2016-02-17       Impact factor: 4.249

9.  The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo.

Authors:  M S Grace; T Lieu; B Darby; F C Abogadie; N Veldhuis; N W Bunnett; P McIntyre
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

10.  A TRPV4 channel C-terminal folding recognition domain critical for trafficking and function.

Authors:  Lei Lei; Xu Cao; Fan Yang; Di-Jing Shi; Yi-Quan Tang; Jie Zheng; KeWei Wang
Journal:  J Biol Chem       Date:  2013-03-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.